Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JL18008 in HIV-Infected Immunological Non-Responders
NCT07443228Phase 1Not yet recruiting
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
- Start
- May 2026
- Primary completion
- Dec 2029
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 1, randomised, double-blind trial of JL18008 in human immunodeficiency virus infection (HIV), sponsored by Jecho Biopharmaceuticals Co., Ltd. Primary endpoint: Safety of JL18008 at 3 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
JL18008
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07443228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07443228.